Arbutus Biopharma Corporation (LON:0SGC)

Arbutus Biopharma Statistics

Total Valuation

LON:0SGC has a market cap or net worth of GBP 566.15 million. The enterprise value is 500.75 million.

Market Cap	566.15M
Enterprise Value	500.75M

Important Dates

The next estimated earnings date is Thursday, March 5, 2026.

Earnings Date	Mar 5, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	189.49M
Shares Outstanding	n/a
Shares Change (YoY)	+5.88%
Shares Change (QoQ)	-0.32%
Owned by Insiders (%)	1.57%
Owned by Institutions (%)	47.32%
Float	124.53M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	52.10
PB Ratio	9.83
P/TBV Ratio	9.83
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-15.92
EV / Sales	46.70
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-14.84

Financial Position

The company has a current ratio of 18.80, with a Debt / Equity ratio of 0.06.

Current Ratio	18.80
Quick Ratio	18.31
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	-0.10
Interest Coverage	-287.66

Financial Efficiency

Return on equity (ROE) is -45.88% and return on invested capital (ROIC) is -20.03%.

Return on Equity (ROE)	-45.88%
Return on Assets (ROA)	-16.46%
Return on Invested Capital (ROIC)	-20.03%
Return on Capital Employed (ROCE)	-33.89%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	246,954
Profits Per Employee	-714,808
Employee Count	44
Asset Turnover	0.12
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +35.03% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+35.03%
50-Day Moving Average	3.39
200-Day Moving Average	3.46
Relative Strength Index (RSI)	49.03
Average Volume (20 Days)	1,640

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.06

Income Statement

In the last 12 months, LON:0SGC had revenue of GBP 10.87 million and -31.45 million in losses. Loss per share was -0.17.

Revenue	10.87M
Gross Profit	-10.74M
Operating Income	-23.33M
Pretax Income	-31.45M
Net Income	-31.45M
EBITDA	-22.82M
EBIT	-23.33M
Loss Per Share	-0.17

Balance Sheet

The company has 69.71 million in cash and 3.43 million in debt, with a net cash position of 66.28 million.

Cash & Cash Equivalents	69.71M
Total Debt	3.43M
Net Cash	66.28M
Net Cash Per Share	n/a
Equity (Book Value)	57.58M
Book Value Per Share	0.30
Working Capital	68.63M

Cash Flow

In the last 12 months, operating cash flow was -33.68 million and capital expenditures -63,979, giving a free cash flow of -33.74 million.

Operating Cash Flow	-33.68M
Capital Expenditures	-63,979
Free Cash Flow	-33.74M
FCF Per Share	n/a

Margins

Gross margin is -98.86%, with operating and profit margins of -214.67% and -289.45%.

Gross Margin	-98.86%
Operating Margin	-214.67%
Pretax Margin	-289.45%
Profit Margin	-289.45%
EBITDA Margin	-209.98%
EBIT Margin	-214.67%
FCF Margin	n/a

Dividends & Yields

LON:0SGC does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.88%
Shareholder Yield	-5.88%
Earnings Yield	-5.56%
FCF Yield	-5.96%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0SGC has an Altman Z-Score of 0.23 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.23
Piotroski F-Score	4